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Abstract
Background: Cerebrospinal fluid (CSF) biomarkers are increasingly being used for diagnosis of Alzheimer’s disease (AD).
Objective: We investigated the influence of CSF intralaboratory and interlaboratory variability on diagnostic CSF-based AD
classification of subjects and identified causes of this variation.
Methods: We measured CSF amyloid-b (Ab) 1-42, total tau (t-tau), and phosphorylated tau (p-tau) by INNOTEST enzyme-
linked-immunosorbent assays (ELISA) in a memory clinic population (n = 126). Samples were measured twice in a single or
two laboratories that served as reference labs for CSF analyses in the Netherlands. Predefined cut-offs were used to classify
CSF biomarkers as normal or abnormal/AD pattern.
Results: CSF intralaboratory variability was higher for Ab1-42 than for t-tau and p-tau. Reanalysis led to a change in
biomarker classification (normal vs. abnormal) of 26% of the subjects based on Ab1-42, 10% based on t-tau, and 29% based
on p-tau. The changes in absolute biomarker concentrations were paralleled by a similar change in levels of internal control
samples between different assay lots. CSF interlaboratory variability was higher for p-tau than for Ab1-42 and t-tau, and
reanalysis led to a change in biomarker classification of 12% of the subjects based on Ab1-42, 1% based on t-tau, and 22%
based on p-tau.
Conclusions: Intralaboratory and interlaboratory CSF variability frequently led to change in diagnostic CSF-based AD
classification for Ab1-42 and p-tau. Lot-to-lot variation was a major cause of intralaboratory variability. This will have
implications for the use of these biomarkers in clinical practice.
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Introduction
Amyloid-b (Ab) 1-42, total tau (t-tau), and phosphorylated tau
(p-tau) proteins in cerebrospinal fluid (CSF) are well-established
biomarkers for Alzheimer’s disease (AD) [1–3], and are increas-
ingly being used for diagnosis in clinical practice. Previous studies
reported considerable intra- or interlaboratory variability of CSF
analyses [4–7], which may influence the diagnostic classification.
In this study, we performed a large-scale CSF multicenter study
and investigated the exact influence of intra- and interlaboratory
variability on CSF-based AD classification of subjects.
We hypothesized that the change of diagnosis would be largest
for classification of subjects based on CSF Ab1-42, as previous
studies showed larger variability for CSF Ab1-42 than for t-tau
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and p-tau [5–7]. It was also hypothesized that change of diagnosis
would be lower for analyses performed in the same laboratory
than for analyses performed in different laboratories because CSF
intralaboratory variability has been reported to be lower than
interlaboratory variability (2.3–25% vs. 13–38%) [5–7].
We investigated intralaboratory and interlaboratory variability
of CSF Ab1-42, t-tau, and p-tau analyses by INNOTEST enzyme-
linked-immunosorbent assays (ELISA). Samples were measured
twice in one or two laboratories that served as reference labs for
AD CSF analyses in the Netherlands. We classified subjects based
on validated cut-offs and examined how often CSF-based AD
diagnosis changed after the second analysis.
Figure 1. CSF levels by analysis and marker. Results are frequencies and mean (SD) for each CSF marker on the left (A) for CSF intralaboratory
analyses and on the right (B) for CSF interlaboratory analyses. The solid line represents the mean CSF levels. Analysis 1 is routine practice and analysis
2 is performed as part of the LeARN study. CSF = cerebrospinal fluid, Ab= amyloid beta, t-tau= total tau, p-tau= phosphorylated tau. **P,0.001, *p,
0.05 compared to CSF analysis 1 or lab 1.
doi:10.1371/journal.pone.0100784.g001
CSF-Based Alzheimer’s Disease Diagnosis
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Materials and Methods
CSF Samples
CSF samples were collected from subjects included in the
Leiden Alzheimer Research Netherlands (LeARN) study [8].
LeARN is a Dutch multicenter study performed in a memory-
clinic setting that included subjects between October 2009 and
May 2011 that had been newly referred for the assessment of
cognitive complaints. Inclusion criteria were baseline diagnosis of
subjective cognitive impairment (SCI), mild cognitive impairment
(MCI) or dementia, Mini-Mental State Examination (MMSE)$
20, clinical dementia rating scale (CDR) of maximal 1. Exclusion
criteria were somatic, psychiatric or neurological disorders that
could have caused the cognitive impairment.
In 3 of the 4 participating centers (Amsterdam, Maastricht, and
Nijmegen), 126 CSF samples were analyzed in twofold, the first
time as part of clinical routine and secondly for the LeARN study
(Figure S1). For routine practice, samples were analyzed in
Amsterdam and Nijmegen, which serve as national CSF AD
biomarker centers. For the LeARN study, all samples were
analyzed in a single batch in Amsterdam. The samples collected in
Amsterdam (n= 50) were measured twice in the same lab and
were used to assess intralaboratory variability. Samples collected in
Nijmegen (n = 32) and Maastricht (n = 44) were measured twice in
different laboratories, i.e. in Nijmegen for clinical routine and in
Amsterdam for the LeARN study, and were used to study
interlaboratory variability (total n = 76). Table S1 provides
baseline patient demographics. The medical research ethics
committee in Maastricht and the institutional review boards of
Maastricht University Medical Center, VU Univeristy Medical
Center Amsterdam, Radboud University Nijmegen Medical
Center, and Leiden University Medical Center approved the
study. All subjects provided written informed consent.
CSF Procedures and Analyses
CSF was obtained by lumbar puncture between the L3/L4 or
L4/L5 intervertebral space, and collected and aliquoted into
polypropylene tubes. Samples for clinical routine of Maastricht
were transported the same day on room temperature or stored at
220uC and transported on dry ice within one week to the
Nijmegen laboratory for analysis. Samples for clinical routine
analysis were stored at 220uC for up to 4 weeks (Amsterdam
cohort) or at 280uC for up to 2 weeks (Maastricht/Nijmegen
cohort) before analysis. Research samples (i.e. samples of the
LeARN study) were stored at 280uC [9], at each center and
samples of Maastricht and Nijmegen were transported on dry ice
to Amsterdam for analysis after up to 2.5 years. Both laboratories
used the commercially available INNOTEST enzyme-linked
immunosorbent assays (ELISAs; Innogenetics, Ghent, Belgium)
to quantify CSF Ab1-42, CSF t-tau, and CSF p-tau, all performed
by experienced laboratory technicians. For analysis of the research
samples, the same lot number was used for all analyses, while for
clinical routine analyses different lots were used in Nijmegen as
well as in Amsterdam. Due to insufficient fluid material, CSF p-tau
values were only available for 49 samples for intralaboratory
analyses.
We also analyzed internal control samples from the Amsterdam
lab to investigate the influence of lot-to-lot variation on measured
CSF concentrations. One control sample had an AD typical
profile and the other a normal CSF profile. The internal controls
were aliquots for single use obtained by pooling surplus CSF.
These aliquots were stored at280uC and all internal controls used
in the current study were from the same batch of pools.
To study differences in biomarker classification as normal versus
abnormal between CSF measurements, we dichotomized the CSF
variables according to routinely used validated cut-offs of each lab.
In Amsterdam, cut-offs were determined that could differentiate
subjects with SCI from subjects with AD-type dementia with 85%
sensitivity: CSF Ab1-42#550 pg/ml, t-tau.375 pg/ml, and p-
tau.52 pg/ml [10]. In Nijmegen, cut-offs were determined that
could differentiate cognitively normal controls from subjects with
AD-type dementia with a specificity of 95%: CSF Ab1-42,
500 pg/ml, t-tau.350 pg/ml, and p-tau.85 pg/ml [11]. Given
that a different approach was used to define cut-offs in Amsterdam
and Nijmegen, we performed interlaboratory analyses with the
same cut-offs (Amsterdam cut-offs) as well as with lab-specific cut-
offs (Amsterdam and Nijmegen cut-offs).
Statistical Analyses
Statistical analyses were done with SPSS version 19.0 (Chicago,
IL, USA) and GraphPad Prism 5, with significance set at p,0.05.
Intralaboratory and interlaboratory coefficients of variation (CV)
were calculated as the standard deviation (SD) divided by the
mean of the measurements of each sample for each biomarker.
Subsequently, a mean CV was calculated. We performed paired t-
tests to investigate the intralaboratory and interlaboratory
variability between CSF analyses of CSF Ab1-42, t-tau, and p-
tau. In addition, we calculated Pearson correlations r and
Intraclass Correlation Coefficients (ICC). An ICC score ranges
from 0 to 1, representing virtually no (0.00–0.10), a slight (0.11–
0.40), fair (0.41–0.60), moderate (0.61–0.80), or substantial (0.81–
1.00) level of agreement between the analyses [12]. Confidence
intervals were calculated for both the Pearson correlations and
ICC scores. We made Bland-Altman plots to visualize the
agreement between the CSF analyses [13], and calculated the
percentage of subjects with change of AD marker classification
Table 1. Agreement between CSF analyses.
Intralaboratory analyses Interlaboratory analyses
Correlation* ICC* Correlation* ICC*
CSF Ab1-42 0.85 (0.74–0.91) 0.76 (0.43–0.89) 0.94 (0.91–0.96) 0.92 (0.85–0.96)
CSF t-tau 0.98 (0.97–0.99) 0.97 (0.92–0.99) 0.98 (0.96–0.99) 0.98 (0.96–0.99)
CSF p-tau 0.95 (0.92–0.97) 0.90 (0.53–0.97) 0.94 (0.90–0.96) 0.73 (0.07–0.92)
Results are Pearson correlation and ICC (95% CI) for intra- and interlaboratory CSF analyses. ICC= Intraclass coefficients, ratio =Ab1-42/t-tau, CSF = cerebrospinal fluid,
Ab= amyloid beta, t-tau = total tau, p-tau = phosphorylated tau.
*All p,0.001.
doi:10.1371/journal.pone.0100784.t001
CSF-Based Alzheimer’s Disease Diagnosis
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after the second analysis using routine CSF cut-offs of each
laboratory. Interlaboratory lot-to-lot variation was examined using
Deming regression [14].
Results
Intralaboratory Variability
CSF Ab1-42 and t-tau levels were higher and p-tau levels were
lower after reanalysis in the same laboratory (p,0.05 for all
analysis, Figure 1A, Figure S2A). The mean intralaboratory CV
was 14.4% for Ab1-42, 8.5% for t-tau, and 12.6% for p-tau. For
CSF Ab1-42, the correlation (0.85) and ICC (0.76) were moderate
and lower than that of CSF t-tau (r=0.98 and ICC=0.97) and
p-tau (r=0.95 and ICC=0.90; Table 1, Figure 2A). Internal
quality control samples that were analyzed at each measurement
also showed higher Ab1-42 levels, slightly higher t-tau levels, and
lower p-tau levels in the second measurement compared to the first
measurement (Figure 3). For the clinical analyses 2 lots were used
Figure 2. Bland-Altman plots of variability between CSF analyses. The average of CSF analysis 1 and 2 is plotted against the difference
between both analyses, on the left (A) for CSF intralaboratory analyses and on the right (B) for CSF interlaboratory analyses. The solid line represents
the mean and the dotted lines the upper and lower 1.95 SD. CSF = cerebrospinal fluid, Ab= amyloid beta, t-tau = total tau, p-tau =phosphorylated
tau.
doi:10.1371/journal.pone.0100784.g002
CSF-Based Alzheimer’s Disease Diagnosis
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(lot 1 and lot 2), although the majority was measured with the
same lot (lot 1). The reanalysis of all samples was performed with
another lot (lot 3). Head-to-head comparison of lot 1 and lot 3 for
the samples in our study showed that particularly the difference in
Ab1-42 levels between measurements could be explained by lot-to-
lot variation although the mean t-tau levels also differed between
lot 1 and 3 (Figure 4).
Interlaboratory Variability
CSF Ab1-42 levels were lower, t-tau levels higher, and p-tau
levels lower after reanalysis in the second laboratory (p,0.05 for
all analysis, Figure 1B, Figure S2B). The interlaboratory CV was
7.3% for Ab1-42, 6.7% for t-tau, and 27.6% for p-tau. For CSF
p-tau, the correlation (0.94) and the ICC (0.73) were high to
moderate and lower than that of CSF Ab1-42 (r=0.94 and
ICC=0.92) and t-tau (r=0.98 and ICC=0.98; Table 1,
Figure 2B).
Change in AD Classification
We investigated how reanalysis changed the CSF AD classifi-
cation based on individual CSF markers and based on the
combination of CSF markers with an AD profile being defined as
abnormal Ab1-42 and abnormal t-tau or p-tau. Using predefined
cutoffs, repeated CSF analyses in the same laboratory led to a
change in biomarker classification (normal vs. abnormal) of 26%
of subjects based on Ab1-42, 10% based on t-tau, 29% based on
p-tau, and 16% based on the AD profile (Table 2). Repeated CSF
analyses in different laboratories using the cut-offs from the
Amsterdam lab led to a change in biomarker classification of 12%
of subjects based on CSF Ab1-42, 1% based on t-tau, 22% based
on p-tau, and 14% based on the AD profile (Table 2). When we
applied lab-specific cut-offs to define an abnormal score, the
repeated CSF analyses in different laboratories led to a change in
biomarker classification of 17% of subjects based on CSF Ab1-42,
1% based on t-tau, 12% based on p-tau, and 12% based on the
AD profile (Table 2). Figure 5 shows the change in CSF levels for
each biomarker for intra- and interlaboratory analyses of subjects
in whom reanalysis led to a different biomarker classification as
normal vs. abnormal when Amsterdam cut-offs were applied.
While most of the subjects with a change in AD classification after
reanalysis in the same laboratory as well as in a different
laboratory had CSF biomarker values relatively close to the cut-
off points, some showed larger changes in CSF biomarker values.
The mean change in CSF values for intralaboratory analyses was
177 pg/ml (95% CI 78–275) for Ab1-42, 72 (13–130) for t-tau,
and 12 (9–16) for p-tau. For interlaboratory analyses with the
Amsterdam cut-offs, the mean change in CSF biomarker values
was 153 pg/ml (57–250) for Ab1-42 and 26 (20–32) for p-tau. For
t-tau, only one subjects showed a change in biochemical diagnosis
(a change of 44 pg/ml).
Discussion
We observed clear variability in CSF AD biomarker levels
between repeated analyses in the same laboratory as well as
between two different laboratories. Our study is the first to show
that this variability frequently led to a change in CSF-based AD
diagnosis when predefined cut-offs for abnormal CSF values were
applied.
CSF intralaboratory variability (based on CV) was largest for
Ab1-42, consistent with previous studies [5–7]. Change in AD-like
scores after repeated analyses in the same laboratory was,
however, highest for CSF p-tau (29%) followed by Ab1-42
(26%) and t-tau (10%). This large change for p-tau is likely due
to a smaller range of values of p-tau and values being closer to the
cut-off compared to other markers, such that a small change in
observed concentration more easily leads to a different classifica-
tion.
CSF interlaboratory variability (based on CV) was largest for
p-tau, unlike findings from previous studies, which found that
interlaboratory variability was largest for Ab1-42 [5–7]. Change in
AD-like scores after repeated analyses in different laboratories was
also higher for CSF p-tau (22%) than for Ab1-42 (12%) and t-tau
(1%) when the same cut-offs were used for each site. A rather
unexpected finding was that the interlaboratory variability of Ab1-
42 was smaller than the intralaboratory variability.
A major finding was that CSF analytical variability frequently
led to a change in diagnostic CSF-based AD classification.
Importantly, also a diagnosis of a CSF AD profile based on
Ab1-42 and t-tau or p-tau changed in 12–16% of the cases. As
some of the subjects whose AD classification changed after
reanalysis had values around the cut-off points, it could be helpful
to use a range around a cut-off point rather than a fixed cut-off
point.
The intra- and interlaboratory variability in CSF results can
result from differences in preanalytical and analytical procedures,
and lot-to-lot variation of analytical kits [9,15]. The intralabora-
Figure 3. Internal control data of the Amsterdam laboratory. Results are changes in high and low CSF biomarker levels for intralaboratory
reanalysis in two lots (routine lot and LeARN lot) as part of internal control of data at the Amsterdam laboratory. A) Ab1-42: Lot 1 used from February
2010 to February 2011 (n = 18) and lot 2 used from March to October 2012 (n = 17). B) T-tau: Lot 1 used from February 2010 to April 2011 (n = 24) and
lot 2 used from March to June 2012 (n = 11). C) P-tau: Lot 1 used from February 2010 to April 2011 (n = 23) and lot 2 used from March to October 2012
(n = 11). CSF = cerebrospinal fluid, Ab= amyloid beta, t-tau = total tau, p-tau= phosphorylated tau. *P,0.001 for differences between lot of analysis 1
(routine lot) and lot of analysis 2 (LeARN lot).
doi:10.1371/journal.pone.0100784.g003
CSF-Based Alzheimer’s Disease Diagnosis
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Figure 4. Intralaboratory lot-to-lot variation. Results in this graph
are based on deming regression and show the CSF levels of lot 1 and lot
3 for Ab1-42 (A), t-tau (B), and p-tau (C). The slope is different for Ab1-42
levels between lot 1 and lot 3. The mean difference in CSF levels
between lot 1 and 3 was significantly different for Ab1-42 and t-tau. Lot
1 = clinical routine lot, lot 3 = LeARN lot, Ab= amyloid beta, t-tau = total
tau, p-tau= phosphorylated tau.
doi:10.1371/journal.pone.0100784.g004 T
a
b
le
2
.
N
u
m
b
e
rs
o
f
su
b
je
ct
s
w
it
h
n
o
rm
al
an
d
ab
n
o
rm
al
cl
as
si
fi
e
d
C
SF
m
ar
ke
r
va
lu
e
s
b
as
e
d
o
n
p
re
d
e
fi
n
e
d
cu
t-
o
ff
s.
In
tr
a
la
b
o
ra
to
ry
a
n
a
ly
se
s
In
te
rl
a
b
o
ra
to
ry
a
n
a
ly
se
s
A
m
st
e
rd
a
m
cu
t-
o
ff
s
A
m
st
e
rd
a
m
cu
t-
o
ff
s*
L
a
b
-s
p
e
ci
fi
c
cu
t-
o
ff
s*
*
C
la
ss
if
ic
a
ti
o
n
o
f
b
io
m
a
rk
e
r(
s)
A
b
1
-4
2
T
-t
a
u
P
-t
a
u
A
D
p
ro
fi
le
A
b
1
-4
2
T
-t
a
u
P
-t
a
u
A
D
p
ro
fi
le
A
b
1
-4
2
T
-t
a
u
P
-t
a
u
A
D
p
ro
fi
le
A
n
al
ys
is
1
&
2
sa
m
e
cl
as
si
fi
ca
ti
o
n
7
4
%
(3
7
)
9
0
%
(4
5
)
7
1
%
(3
5
)
8
4
%
(4
2
)
8
8
%
(6
7
)
9
9
%
(7
5
)
7
8
%
(5
9
)
8
6
%
(6
5
)
8
3
%
(6
3
)
9
9
%
(7
5
)
8
8
%
(6
7
)
8
8
%
(6
7
)
A
n
al
ys
is
1
n
o
rm
al
&
2
ab
n
o
rm
al
2
%
(1
)
4
%
(2
)
6
%
(3
)
-
1
1
%
(8
)
-
-
9
%
(7
)
1
6
%
(1
2
)
-
1
1
%
(8
)
1
2
%
(9
)
A
n
al
ys
is
1
ab
n
o
rm
al
&
2
n
o
rm
al
2
4
%
(1
2
)
6
%
(3
)
2
3
%
(1
1
)
1
6
%
(8
)
1
%
(1
)
1
%
(1
)
2
2
%
(1
7
)
5
%
(4
)
1
%
(1
)
1
%
(1
)
1
%
(1
)
-
R
e
su
lt
s
ar
e
th
e
p
e
rc
e
n
ta
g
e
(n
u
m
b
e
r)
o
f
su
b
je
ct
s
w
it
h
n
o
rm
al
an
d
ab
n
o
rm
al
cl
as
si
fi
e
d
C
SF
m
ar
ke
rs
b
as
e
d
o
n
C
SF
an
al
ys
is
1
(r
o
u
ti
n
e
p
ra
ct
ic
e
)
an
d
an
al
ys
is
2
(L
e
A
R
N
st
u
d
y)
.T
h
e
C
SF
A
D
p
ro
fi
le
w
as
d
e
fi
n
e
d
as
ab
n
o
rm
al
A
b
1
-4
2
an
d
ab
n
o
rm
al
t-
ta
u
o
r
p
-t
au
,
b
as
e
d
o
n
p
re
d
e
fi
n
e
d
cu
t-
o
ff
s
(s
e
e
m
e
th
o
d
s)
.
C
SF
=
ce
re
b
ro
sp
in
al
fl
u
id
,
A
b
=
am
yl
o
id
b
e
ta
,
t-
ta
u
=
to
ta
l
ta
u
,
p
-t
au
=
p
h
o
sp
h
o
ry
la
te
d
ta
u
.
*T
h
e
ro
u
ti
n
e
an
al
ys
e
s
in
N
ijm
e
g
e
n
an
d
th
e
Le
A
R
N
an
al
ys
e
s
w
e
re
d
ic
h
o
to
m
iz
e
d
ac
co
rd
in
g
to
th
e
A
m
st
e
rd
am
cu
t-
o
ff
s
(s
e
e
m
e
th
o
d
s)
.
**
T
h
e
ro
u
ti
n
e
an
al
ys
e
s
in
N
ijm
e
g
e
n
w
e
re
d
ic
h
o
to
m
iz
e
d
ac
co
rd
in
g
to
th
e
N
ijm
e
g
e
n
cu
t-
o
ff
s
an
d
th
e
Le
A
R
N
an
al
ys
e
s
ac
co
rd
in
g
to
th
e
A
m
st
e
rd
am
cu
t-
o
ff
s
(s
e
e
m
e
th
o
d
s)
.
d
o
i:1
0
.1
3
7
1
/j
o
u
rn
al
.p
o
n
e
.0
1
0
0
7
8
4
.t
0
0
2
CSF-Based Alzheimer’s Disease Diagnosis
PLOS ONE | www.plosone.org 6 June 2014 | Volume 9 | Issue 6 | e100784
Figure 5. Change in CSF marker classification according to cut-offs. Results are CSF levels only for subjects in which reanalysis let to a
different biomarker classification using the cut-offs from Amsterdam to define abnormal CSF values. On the left (A) are changes in biomarker levels
for intralaboratory reanalysis and on the right (B) for interlaboratory reanalysis. The arrow represents the applied Amsterdam CSF cut-off. Analysis 1 is
routine practice and analysis 2 is performed as part of the LeARN study. CSF = cerebrospinal fluid, Ab= amyloid beta, t-tau = total tau, p-
tau = phosphorylated tau.
doi:10.1371/journal.pone.0100784.g005
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tory variability is likely mainly due to lot-to-lot variation as other
procedures remained essentially the same. Lot-to-lot variation is a
technical limitation of the ELISA method, which should also be
considered when defining cut-offs and interpreting CSF values
close to the cut-off. Additional support for this comes from our
observation that internal control values showed a striking lot-to-lot
variation of up to 20%. The change in internal control values was
of the same order of magnitude and same direction of change as
the change in CSF scores from the patient samples. Head-to head
comparison of lots for the samples in our study showed that mainly
CSF Ab1-42 variability could be explained by lot-to-lot variation.
This likely explains why CSF intralaboratory variability was
largest for Ab1-42. Another possible explanation for the
intralaboratory variability is variability in freezing conditions and
storage time. However, previous studies showed that these factors
have a minor impact on variability of CSF values [16,17].
Interlaboratory variability may also be caused by lot-to-lot
variation. Indeed, lots used in each lab showed only minor overlap
(data not shown). Differences in analytical procedures may also
have contributed to the interlaboratory variability. However, both
laboratories used similar protocols, were both trained in a hands-
on workshop [9], and were similarly experienced.
Another source of variability between laboratories, which may
influence CSF-based AD classification, is the difference in cut-offs
used. We, therefore, tested interlaboratory variability for CSF-
based AD classification both with the same CSF cut-offs as well as
lab-specific cut-offs. While lab-specific cut-offs for Ab1-42 and
t-tau did not differ much, there was a large difference for p-tau
(85 pg/ml in Nijmegen vs. 52 pg/ml in Amsterdam). This was also
reflected in the interlaboratory variability in CSF-based AD
classification. Using the same cut-off, abnormal p-tau was more
common when samples were analyzed in Nijmegen than in
Amsterdam. Change in classification was often due to subjects
with scores around the cut-off (Figure 5B). Using the lab-specific
cut-off, however, abnormal p-tau was more common when
samples were analyzed in Amsterdam than in Nijmegen. Here
change in classification was mainly due to differences in cut-offs.
This clearly indicates that lab-specific cut-offs may also influence
comparability between laboratories.
Our study has several limitations. The cut-offs that were used
may have influenced our findings on change in CSF-based AD
diagnosis. However, as no universal CSF cut-offs are available, we
applied routinely used validated cut-offs.
One of the major strengths of this study was the large number of
CSF samples used to study interlaboratory variability, as most
previous studies were based only on a few samples [5–7].
Furthermore, our study is the first to show head-to-head
comparison of lots within one center to directly address the issue
of lot-to-lot variability. Therefore, our findings may provide a
valuable addition to the described findings of the Alzheimer
Association Quality Control program. In addition, our study
design allows generalization to other CSF centers that analyze
CSF AD biomarkers using ELISA, as it reflects CSF procedures in
general clinical practice.
Together, our findings suggest that variability in CSF analyses is
common between and within laboratories, in particular for Ab1-
42 and p-tau. A substantial part of this variability seems to be
explained by lot-to-lot variation of analytical kits. The variability
has a large impact on CSF-based AD diagnosis or treatment
decisions in clinical settings, suggesting that we should be careful
when interpreting CSF findings and always interpret them within
a clinical context [18], and with reference to internal standards.
Also the use of age-adjusted cut-offs may be helpful, as tau levels
are known to increase with age.
For the moment this rightly restricts the indication for CSF
biomarker testing in diagnostic guidelines as complimentary and
non-obligatory [19,20]. The recent consensus on standardization
of preanalytical aspects of CSF analyses [15,17], as well as the
ongoing worldwide quality control study [6], and standardization
projects (www.neurodegenerationresearch.eu) will help to move
towards a standardized and harmonized implementation of CSF
markers in clinical routine.
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